Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $48.69M rose 85.5% year over year, ahead of the +66.9% change in trailing-twelve-month research & development. Sequentially, it rose 41.0% from the prior quarter. Over 3 fiscal years it compounded at +70.5% a year.
Context
- Research & development amounted to 7153.1% of revenue in FY2025, up 5820.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +85.5% holds above the trailing-twelve-month pace of +66.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 145.64M USD
- Year-over-year change
- +75.2%
- 4-year CAGR
- +84.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 145.64M | +75.2% |
| FY2024 | 2024-12-31 | 83.11M | +153.1% |
| FY2023 | 2023-12-31 | 32.84M | +11.8% |
| FY2022 | 2022-12-31 | 29.38M | +133.1% |
| FY2021 | 2021-12-31 | 12.61M | — |
Research & Development vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 research & development of $175.6M is the 5th highest of the 10 companies compared; the peer median is $128.65M.
- Its year-over-year change of +66.9% is the highest of 10, against a peer median of +25.5%.
- Research & development amounts to 9222.6% of revenue for DNTH, versus a peer median of 4112.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M | +16.2% | +41.8% | 6608.2% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M | +27.7% | +16.5% | — |
| LTM Mar 2026 | $62.82M | +25.5% | -7.1% | 3539.3% | |
| FY2025 | $37.8M | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $15.25M | -66.4% | -18.8% | 28.4% | |
| Peer median (excluding DNTH) | $128.65M | +25.5% | +16.5% | 4112.4% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| Weighted Avg Shares | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
| Weighted Avg Shares (Diluted) | 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.